← Back to Search

Monoclonal Antibodies

casirivimab+imdevimab for COVID-19

Phase 2
Recruiting
Research Sponsored by Regeneron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 32 weeks
Awards & highlights

Study Summary

This trial is testing a new antibody combination drug given by injection under the skin. The goal is to see how well it works and if it is safe.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 32 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 32 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Concentrations of casirivimab+imdevimab in serum over time.
Secondary outcome measures
Immunogenicity as measured by ADA to imdevimab over time
Immunogenicity as measured by NAb to imdevimab over time
Immunogenicity as measured by anti-drug antibodies (ADA) to casirivimab over time
+5 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: ≥5 kg to <10 kgExperimental Treatment1 Intervention
SC administration
Group II: ≥3 kg to <5 kgExperimental Treatment1 Intervention
SC administration
Group III: ≥20 kg to <40 kgExperimental Treatment1 Intervention
SC administration
Group IV: ≥10 kg to <20 kgExperimental Treatment1 Intervention
SC administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Anti-SARS-CoV-2 REGN-COV2
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
618 Previous Clinical Trials
380,205 Total Patients Enrolled
13 Trials studying COVID-19
19,102 Patients Enrolled for COVID-19
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
260 Previous Clinical Trials
251,014 Total Patients Enrolled
10 Trials studying COVID-19
18,842 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Stony Brook University Hospital
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
2021. "COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05149300.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top